Silence Therapeutics Plc American Depository Share - SLN STOCK NEWS

The report titled "Polycythemia Vera Market Insights, Epidemiology, and Market Forecast -2032" offers a comprehensive analysis of the Polycythemia Vera market. In 2022, the U.S. Polycythemia Vera market size was approximately USD 1,500 million and is projected to grow through 2032. The report highlights that PharmaEssentia's Besremi is the only first-line therapy approved, while Incyte's Jakafi is the sole second-line treatment. Additionally, competition may arise from Protagonist Therapeutics' Rusfertide and Imago Biosciences' Bomedemstat, expected to launch in late 2024 and 2026 respectively. The report also discusses emerging therapies with potential market impact, including Silence Therapeutics' SLN124.

The Global Small Interfering RNA (SiRNA) Market is projected to reach $964.17 Million by 2030, with a CAGR of 8.6% from 2023 to 2030. Key insights show that liposome-based systemic therapy represents 52.01% of the market share. The cancer segment leads therapeutics with a 38.14% share, while research institutions account for 43.07% of applications. North America dominated the market in 2022 due to robust R&D activities. Significant partnerships, such as Silence Therapeutics with Hansoh Pharmaceutical, are accelerating market growth in the APAC region. The report emphasizes a focus on RNA functions and its therapeutic potential for various genetic disorders.

Silence Therapeutics plc, trading on Nasdaq under the symbol SLN, will have its President and CEO, Craig Tooman, present at the virtual SVB Securities Global Biopharma Conference on February 15 at 3:00 p.m. ET. The presentation will be accessible via the Investors section of the company’s website. Silence is focused on innovating precision medicines through RNA interference technology, targeting diseases with significant unmet needs. Key product candidates include SLN360 for cardiovascular risk and SLN124 for hematological diseases, complemented by collaborations with notable partners like AstraZeneca.

Silence Therapeutics plc, trading under Nasdaq: SLN, has appointed J.P. Gabriel as Chief Technical Operations Officer following the retirement of Jørgen Wittendorff. Gabriel brings over 25 years of experience in supply chain and manufacturing, crucial for advancing the company's clinical pipeline. Silence focuses on RNA interference technology to target genetic diseases and has product candidates like SLN360 and SLN124. The company also collaborates with AstraZeneca and other firms to enhance its research initiatives.

Silence Therapeutics plc (NASDAQ: SLN) presented key updates on its SLN360 and SLN124 programs at the 41st Annual J.P. Morgan Healthcare Conference. The SLN360 phase 2 study for high-risk atherosclerotic cardiovascular disease has begun dosing, with enrollment completion expected by Q4 2023. Preliminary data from the phase 1 study indicate significant reductions in lipoprotein(a) levels. Additionally, the SLN124 phase 1/2 study for polycythemia vera is now enrolling participants, with data from thalassemia patients expected in Q4 2023. Silence anticipates a pivotal year ahead.

Silence Therapeutics, trading under the ticker SLN, will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 12 at 9:45 a.m. PT. The presentation by Craig Tooman, CEO, highlights the company's commitment to innovative biotechnology solutions aimed at silencing diseases through RNA interference. A live webcast will be available on the Silence Therapeutics website, with an archived replay to follow after the event.

Silence is focusing on RNAi-based medicines and has ongoing collaborations with leading pharmaceutical companies.

Silence Therapeutics plc (Nasdaq: SLN) reported its Q3 2022 financial results, showcasing a net loss of £7.1 million, an improvement from £9.9 million in Q3 2021. Revenue rose to £3.4 million, driven by collaboration agreements. Key milestones include anticipated phase 2 studies for SLN360 and SLN124, with SLN124 receiving FDA Fast Track Designation. The company's cash position stood at £90.0 million following a successful offering raising $56.5 million in August. This reinforces the company’s commitment to advancing its innovative pipeline.

Silence Therapeutics plc (NASDAQ: SLN) announced that CEO Craig Tooman will present a business overview at the Jefferies London Healthcare Conference on Wednesday, November 16, at 8:00 a.m. GMT. The conference aims to highlight Silence's innovative RNA interference technology, which targets gene silencing to tackle diseases with significant unmet needs. The live presentation will be available via webcast on Silence's website, with an archived replay accessible after the event.

Silence Therapeutics has presented promising data from its APOLLO phase 1 study of SLN360, targeting elevated lipoprotein(a) (Lp(a)), a significant cardiovascular risk factor. Results showed that participants receiving 300 mg and 600 mg doses maintained median reductions in Lp(a) levels exceeding 80% over five months. Some maintained reductions of up to 50% of baseline at one year. No new safety concerns arose, suggesting SLN360's potential for infrequent dosing. The company plans to advance into a phase 2 study for patients with atherosclerosis in late 2022.